FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087955556> ?p ?o ?g. }

• W2087955556 abstract "Abstract Background TZP ‐102, a potent, oral, ghrelin receptor agonist, improved diabetic gastroparesis symptoms in Phase 2a. Methods Patients with type 1 or 2 diabetes, delayed gastric half‐emptying (T 1/2 ), and ≥3 months gastroparesis symptoms randomized 1 : 1 : 1 to double‐blind placebo, 10‐mg, or 20‐mg TZP ‐102 once daily for 12 weeks (Study TZP ‐102‐ CL ‐G003). Study TZP ‐102‐ CL ‐G004 patients randomized 1 : 1 to 10‐mg TZP ‐102:placebo three‐times‐daily. Primary endpoint was change‐from‐baseline through Weeks 11–12 in Daily Diary of Gastroparesis Symptoms Questionnaire ( GSDD ) via electronic Patient Recorded Outcome device: worst severity of nausea, early satiety, bloating, and upper abdominal pain in 24 h (0 = none‐to‐5 = very severe). GSDD Composite Score for eligibility was ≥2.5 (Day‐14‐to‐baseline). Patient Overall Treatment Evaluation ( OTE ) provided an anchor‐based minimal clinically important difference ( MCID ) for GSDD Composite Score. Key Results Study TZP ‐102‐ CL ‐G003 enrolled 201 outpatients: females 72%; Caucasians 87%; type 2 diabetes 61%; insulin‐dependent 65%; age mean ± SD 53 ± 11.3 years; HbA1c 7.8 ± 1.5%; GCSI 3.4 ± 0.7; GSDD Composite 3.6 ± 0.6; gastric T 1/2 131 ± 32 min; n = 69 (10‐mg), n = 66 (20‐mg), n = 66 (placebo). Primary endpoint ( GSDD ): significant improvement in all arms, although not for TZP ‐102 vs placebo: mean change‐from‐baseline −1.7, −1.4, −1.5 (10‐mg, 20‐mg, placebo); Gastroparesis Cardinal Symptom Index −1.8, −1.6, −1.5, respectively. The OTE (all patients) at Week‐12 was: Patient 3.7 ± 3.2 and Physician 3.6 ± 3.0 with median score for both of 5.0 = important on scale of improvement; individual MCID was 1.61 and 0.94 for group analyses, greater than expected. Study TZP ‐102‐ CL ‐G004 with similar demographic/disease characteristics was prematurely terminated for efficacy futility (n = 64 with Week‐4 assessments). Conclusions & Inferences Efficacy of TZP ‐102 was not demonstrated compared with placebo in diabetic gastroparesis; however, there was substantial symptom improvement in all arms ( ClinicalTrials.gov NCT01452815/NCT01664637)." @default.
• W2087955556 created "2016-06-24" @default.
• W2087955556 creator A5005028574 @default.
• W2087955556 creator A5008144271 @default.
• W2087955556 creator A5011149016 @default.
• W2087955556 creator A5014076036 @default.
• W2087955556 creator A5022767708 @default.
• W2087955556 creator A5037407546 @default.
• W2087955556 creator A5037922523 @default.
• W2087955556 creator A5039354063 @default.
• W2087955556 creator A5057242083 @default.
• W2087955556 creator A5084312443 @default.
• W2087955556 date "2013-07-15" @default.
• W2087955556 modified "2023-10-18" @default.
• W2087955556 title "Phase 2b, randomized, double‐blind 12‐week studies of <scp>TZP</scp>‐102, a ghrelin receptor agonist for diabetic gastroparesis" @default.
• W2087955556 cites W1502294688 @default.
• W2087955556 cites W1520349489 @default.
• W2087955556 cites W1525765510 @default.
• W2087955556 cites W1583848026 @default.
• W2087955556 cites W1842959935 @default.
• W2087955556 cites W1964081706 @default.
• W2087955556 cites W1964484977 @default.
• W2087955556 cites W1969888489 @default.
• W2087955556 cites W1971889126 @default.
• W2087955556 cites W1976149361 @default.
• W2087955556 cites W1983928000 @default.
• W2087955556 cites W1991070573 @default.
• W2087955556 cites W1996200834 @default.
• W2087955556 cites W1997587937 @default.
• W2087955556 cites W2003920697 @default.
• W2087955556 cites W2020305363 @default.
• W2087955556 cites W2022832699 @default.
• W2087955556 cites W2033464668 @default.
• W2087955556 cites W2033541852 @default.
• W2087955556 cites W2038810061 @default.
• W2087955556 cites W2047223198 @default.
• W2087955556 cites W2054271473 @default.
• W2087955556 cites W2054782808 @default.
• W2087955556 cites W2056441723 @default.
• W2087955556 cites W2074601711 @default.
• W2087955556 cites W2101611974 @default.
• W2087955556 cites W2122114281 @default.
• W2087955556 cites W2129558138 @default.
• W2087955556 cites W2153335875 @default.
• W2087955556 cites W2155661746 @default.
• W2087955556 cites W2157416528 @default.
• W2087955556 cites W2165046753 @default.
• W2087955556 cites W2171472795 @default.
• W2087955556 cites W58909306 @default.
• W2087955556 doi "https://doi.org/10.1111/nmo.12184" @default.
• W2087955556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23848826" @default.
• W2087955556 hasPublicationYear "2013" @default.
• W2087955556 type Work @default.
• W2087955556 sameAs 2087955556 @default.
• W2087955556 citedByCount "95" @default.
• W2087955556 countsByYear W20879555562013 @default.
• W2087955556 countsByYear W20879555562014 @default.
• W2087955556 countsByYear W20879555562015 @default.
• W2087955556 countsByYear W20879555562016 @default.
• W2087955556 countsByYear W20879555562017 @default.
• W2087955556 countsByYear W20879555562018 @default.
• W2087955556 countsByYear W20879555562019 @default.
• W2087955556 countsByYear W20879555562020 @default.
• W2087955556 countsByYear W20879555562021 @default.
• W2087955556 countsByYear W20879555562022 @default.
• W2087955556 countsByYear W20879555562023 @default.
• W2087955556 crossrefType "journal-article" @default.
• W2087955556 hasAuthorship W2087955556A5005028574 @default.
• W2087955556 hasAuthorship W2087955556A5008144271 @default.
• W2087955556 hasAuthorship W2087955556A5011149016 @default.
• W2087955556 hasAuthorship W2087955556A5014076036 @default.
• W2087955556 hasAuthorship W2087955556A5022767708 @default.
• W2087955556 hasAuthorship W2087955556A5037407546 @default.
• W2087955556 hasAuthorship W2087955556A5037922523 @default.
• W2087955556 hasAuthorship W2087955556A5039354063 @default.
• W2087955556 hasAuthorship W2087955556A5057242083 @default.
• W2087955556 hasAuthorship W2087955556A5084312443 @default.
• W2087955556 hasConcept C126322002 @default.
• W2087955556 hasConcept C134018914 @default.
• W2087955556 hasConcept C142724271 @default.
• W2087955556 hasConcept C168563851 @default.
• W2087955556 hasConcept C170493617 @default.
• W2087955556 hasConcept C203092338 @default.
• W2087955556 hasConcept C204787440 @default.
• W2087955556 hasConcept C27081682 @default.
• W2087955556 hasConcept C2776956441 @default.
• W2087955556 hasConcept C2777180221 @default.
• W2087955556 hasConcept C2778769438 @default.
• W2087955556 hasConcept C2778938600 @default.
• W2087955556 hasConcept C2779357093 @default.
• W2087955556 hasConcept C2779422922 @default.
• W2087955556 hasConcept C2780580376 @default.
• W2087955556 hasConcept C2780955771 @default.
• W2087955556 hasConcept C2781308992 @default.
• W2087955556 hasConcept C3020479747 @default.
• W2087955556 hasConcept C555293320 @default.
• W2087955556 hasConcept C71924100 @default.
• W2087955556 hasConcept C90924648 @default.
• W2087955556 hasConceptScore W2087955556C126322002 @default.
• W2087955556 hasConceptScore W2087955556C134018914 @default.

• next